|
L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- Suppliers list
|
| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- Basic information |
| Product Name: | L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- | | Synonyms: | L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- | | CAS: | 104486-81-9 | | MF: | C26H46CaO9 | | MW: | 542.72 | | EINECS: | | | Product Categories: | | | Mol File: | 104486-81-9.mol | ![L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- Structure](CAS/20211123/GIF/104486-81-9.gif) |
| | L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- Chemical Properties |
| | L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- Usage And Synthesis |
| Uses | Antibacterial (topical). | | Definition | ChEBI: Mupirocin calcium (anhydrous) is the anhydrous form of the calcium salt of mupirocin. The dihydrate form is used as an antibacterial drug for the treatment of skin infections. It has a role as an antibacterial drug and a protein synthesis inhibitor. It contains a mupirocin(1-). | | Brand name | Bactroban (GlaxoSmithKline). | | in vivo | MRSA: Meticillin-resistant Staphylococcus aureus
Mupirocin (BRL-4910A, Pseudomonic acid) calcium is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A[1].
Mupirocin calcium (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment[3].
Mupirocin calcium (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice[4].
Mupirocin calcium (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis[5]. | Animal Model: | MRSA skin infection model in mice (10-12 weeks old)[3] | | Dosage: | 2% ointment | | Administration: | External administration; twice daily; 3-6 days | | Result: | Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log10 CFU on day 3 and 6, respectively.
|
| Animal Model: | Diabetic pressure ulcer mouse model (33.2-39.2 g)[4] | | Dosage: | 2% ointment | | Administration: | External administration; 4 days | | Result: | Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation.
|
| Animal Model: | Adult male Wistar rats (weight 275-325 g)[5] | | Dosage: | Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm2 | | Administration: | Subcutaneous implantation; 7 days | | Result: | Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts.
|
|
| | L-talo-Non-2-enonicacid,5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2S,3S)-3-[(1S,2S)-2-hydroxy-1-methylpropyl]-2-oxiranyl]methyl]-3-methyl-,8-carboxyoctyl ester, calcium salt (2:1), (2E)- Preparation Products And Raw materials |
|